GlassScriptPhysician profile
David M Keller
NPI 1871651968
$5,953.77
in general payments reported to CMS, 2019-2025
63 companies · $838 in 2025
The $838 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,069 · 2020: $409 · 2021: $662 · 2022: $621 · 2023: $1,101 · 2024: $1,254 · 2025: $838.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,193.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,230.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $464.92 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $437.36 | 2019-2025 | Evenity, Prolia |
| Novo Nordisk INC | $416.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $289.33 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Antares Pharma, INC. | $277.13 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Otsuka America Pharmaceutical, INC. | $264.90 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $235.98 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $187.66 | 2023-2025 | |
| Pfizer INC. | $142.23 | 2020-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $127.90 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $124.94 | 2022-2025 | |
| Grifols USA, LLC | $102.60 | 2022-2023 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $90.36 | 2019-2022 | |
| Boston Scientific Corporation | $89.30 | 2019-2024 | Watchman Flx |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Keller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.